Evotec and Takeda enter into multi therapeutic area collaboration
September 24, 2019Manufacturing and Production, Research and Development
Evotec have announced a strategic, multi-year drug discovery collaboration with Takeda, with both companies aiming to establish at least five …
Bayer’s Vitravki becomes first EU-approved tumour-agnostic therapy
September 24, 2019Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Cancer, Vitravki, pharma
Bayer has announced that its tyrosine receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib) has scored approval from the European Commission for …
Medicinal cannabis product Epidyolex approved in EU for childhood epilepsy
September 24, 2019Manufacturing and Production, Research and Development
GW Pharmaceuticals, a world leader in the development of cannabinoid prescription drugs has announced it has received approval from the …
Destiny Pharma’s Joe Eagle to step down from Board
September 23, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs to address the global crisis …
Living with acute myeloid leukaemia
September 23, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing acute myeloid leukaemia, feature, patient experience, pharma
Steve Rothberg was blindsided by an AML diagnosis that progressed rapidly with little warning. Ten years later, he discusses his …
Bluebird bio’s Lenti-D gene therapy shows promise in cerebral adrenoleukodystrophy
September 23, 2019Research and Development, Sales and Marketing Bluebird Bio, cerebral adrenoleukodystrophy, gene therapy, pharma
Bluebird bio has revealed updated data for its investigational Lenti-D gene therapy in the treatment of cerebral adrenoleukodystrophy (CALD), a …
Servier on trial for weight-loss pill that led to 2,000 deaths
September 23, 2019Sales and Marketing
A trial on one of France’s largest ever healthcare scandals has begun after a weight loss pill was believed to …
Japan approves Astellas and FibroGen’s Evrenzo for anaemia in dialysis patients
September 23, 2019Sales and Marketing Astellas, anaemia, fibrogen, pharma
Astellas Pharma and FibroGen have revealed that their collaborative drug Evrenzo (roxadustat) has secured marketing authorisation in Japan for the …
EMA’s CHMP recommends three new medications
September 23, 2019Sales and Marketing
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) have recommended approval for three new medicines with …
FDA approves Novo’s new type 2 diabetes pill
September 23, 2019Sales and Marketing
A new drug from Danish drug maker Novo Nordisk, called Rybelsus (semaglutide), has been approved by the FDA for the …
Top Ten most popular articles on Pharmafile.com this week
September 20, 2019Medical Communications
Friday time! This past week has seen numerous potential breakthroughs including a prostate drug that could halt Parkinson’s disease as …
Antidepressant sertraline works ‘by reducing anxiety symptoms first’
September 20, 2019Medical Communications, Research and Development antidepressant, sertraline
Researchers at University College London have found that a commonly prescribed antidepressant, sertraline, works in unexpected ways, first relieving users …
Novo’s Tresiba lowers hypoglycaemia risk compared to insulin glargine in type 2 diabetes
September 20, 2019Medical Communications, Research and Development Novo Nordisk, Tresiba, diabetes, pharma
Novo Nordisk has unveiled new data for Tresiba (insulin degludec) at the 55th Annual Meeting of the European Association for …
Biogen to start new Spinraza trial to preserve market share
September 20, 2019Medical Communications, Research and Development
Biogen is planning a new trial of $1.7billion-a-year Spinraza to investigate much higher doses in spinal muscular atrophy (SMA) and …
Lundbeck and Takeda’s depression drug approved in Japan
September 20, 2019Medical Communications, Sales and Marketing Japan, Lundbeck, Takeda, major depressive disorder, pharma
Takeda and Lundbeck have announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has chosen to authorise their drug …
Almost half of all cancer drug trials show bias and exaggeration
September 19, 2019Research and Development BMJ, Cancer, cancer drug trials
New research on clinical trials between 2014 and 2016 raise “serious concerns about low standards” as over the three year …
Sanofi’s Troujeo beats insulin degludec in head-to-head study in type 2 diabetes
September 19, 2019Research and Development Sanofi, Troujeo, diabetes, insulin degludec, pharma
Sanofi took the opportunity at the 55th annual European Association for the Study of Diabetes to present new data from …
British baby’s death not caused by Zolgensma says Novartis
September 19, 2019Research and Development AveXis, Novartis, Zolgensma, spinal muscular atrophy
Swiss drugmaker Novartis have stated that a British baby’s death this year after getting Novartis’ gene therapy Zolgensma, was not …
FDA expands Janssen’s Erleada label to cover metastatic castration-sensitive prostate cancer
September 19, 2019Sales and Marketing Cancer, Erleada, FDA, Janssen, pharma, prostate cancer
Janssen has announced that the FDA has expanded the label of its androgen receptor inhibitor Erleada (apalutamide) to include the …
Poor diabetes control costing NHS £3bn in avoidable treatment
September 19, 2019Business Services, Sales and Marketing
Findings being presented at this year’s European Association for the Study of Diabetes have shown that the NHS is losing …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
